GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR IN ADULTS WITH ARTERIAL HYPERTENSION
https://doi.org/10.15829/1560-4071-2015-4-43-48
Abstract
Aim. To compare the concentration of growth hormone, insulin-like growth factor and the specifics of carbohydrate and lipid metabolism in AH patients of the 1st grade and the persons without elevated BP, to reveal a relation of these values with obesity rate and with the gender.
Material and methods. Morning fasting blood was used for growth hormone, insulin-like growth factor, insulin, glucose, total cholesterol, high and low density lipoproteid cholesterol, triglycerides and C-reactive protein measurement in 43 patients with arterial hypertension of the 1st grade with overweight (18 persons) or obesity (25 persons), and in 31 participant with optimal and normal blood pressure with overweight (15 persons) or normal body mass.
Results. The level of growth factor and its effector — insulin-like growth factor was lower (p<0,05) and body mass index was higher (p<0,001) in patients with increased blood pressure than in controls. In the main group also there was higher insulin concentration, higher total cholesterol, triglycerides and C-reactive protein. In comparison of two parameters only for the participants with excess body mass and high or normal blood pressure (excluding growth hormone concentration) all differences disappeared. Comparison of the two parameters mentioned in patients with arterial hypertension with and without obesity also did not reveal intergroup differences.
We did not find gender dimorphism influence on the growth hormone and insulin-like growth factor secretion as well, as on the changes of lipid and carbohydrate metabolism. For the participants from the upper tercile by the level of insulin-like growth factor it was more common to have higher diastolic pressure than in lower tercile.
Conclusion. The decrease of growth hormone concentration and insulin-like growth factor, as the changes in lipid and carbohydrates metabolism are common for the combination of 1 st grade arterial hypertension and obesity, although isolated blood pressure increase or the development of obesity does not influence these parameters significantly.
About the Author
T. A. Mangileva
Medical Academy п. а. С I. Georgievsky of FSAOIHE Crimea Federal University n. a. V. I. Vernadsky, Simferopol, Russia.
Russian Federation
Russian Federation
References
1. Yuen КС, Dunger DB. Therapeutic aspects of growth hormone and insulin-like growth
2. factor treatment on visceral fat and insulin sensitivity in adult. Diabetes Obes.Metab.
3. ;9:11-22.
4. Moller N, Jorgensen 0. Effects of growth hormone on glucose, lipid and protein
5. metabolism in human subjects. Endocrine reviews 2009; 3: 152-77.
6. Puche JE, Castilla-Cortazar E. Human conditions of insulin-like growth factor-1 (IGF-1)
7. deficiency. J. Transl. Med. 2012; 10: 224-2
8. Hypponen E, Boucher BJ, Berry DJ. Power С 25-hydroxyvitamin D, IGF-1, and metabolic
9. syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort.
10. Diabetes 2008; 57: 298-305.
11. Towie DHP, Merriam JR. Hypertension in growth hormone excess and deficiency. In: ed.
12. KochC.H.,ChrousosG.R Endocrine hypertension. Humana Press; 2013:151-79.
13. HigshiY, SukhanovS, Anwar A, etal. Aging, atherosclerosis, and IGF-1. J. Gerontol. A. Biol.
14. Sci. Med. Sci. 2012; 67A: 626-39.
15. Zhang L, Curhan GC, Forman JP. Plasma insulin-like growth factor-1 level and risk of
16. incident hypertension in non-diabetic women. J. Hypertens. 2011; 29: 229-35.
17. Hunt KJ, Lukanova A, Rinaldi S, et al. A potential inverse association between insulin like
18. growth factor-1 and hypertension in cross-sectional study. Ann.Epidemiol. 2006; 16:
19. -71.
20. Colao A, Somma CD, Cascella T, et al. Relationships between serum IGF-1 levels, blood pressure and glucose tolerance: an observational, exploratory study in 404 subjects. Europ.J.Endocrinol. 2008; 159: 389-97.
21. Zachariah JP, XanthakisV, Larson MJ, et al. Circulating vascular growth factors and central hemodynamic load in the community. Hypertension 2012; 59: 773-9.
22. Andronico G, Mangano MT, Nardi E, et al. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J. Hypertens. 1993; 10: 1097-101.
23. Lemne C, BrismarK. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome — a study in borderline hypertension. Blood Press. 1998; 7: 89-95.
24. TivestenA, Barlind A, Caidahl K, etal. Growth hormone-induced blood pressure decrease is associated with increased nRNA levels of the vascular smooth muscle Kalp channel. J. Endocrinol. 2004; 183: 195-202.
25. Faje AT, Barkan AL. Basal, but not pulsatile growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-1. JCEM 2010; 95: 2486-91.
26. Colangelo LA, Liu K, CapsturSM. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and cardiovascular disease risk factors in young black men and white men: the CARDIA male hormone study. Am .J.Epidemiol. 2004; 160: 750-7.
Review
For citations:
Mangileva T.A. GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR IN ADULTS WITH ARTERIAL HYPERTENSION. Russian Journal of Cardiology. 2015;(4):43-48. (In Russ.) https://doi.org/10.15829/1560-4071-2015-4-43-48
Views:
2979
Email this article 